SpringWorks Therapeutics, Inc. (SWTX)

29.18 +0.15 (+0.52%) At close: 04:00PM EDT

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490
https://www.springworkstx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 222

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Saqib Islam J.D.	CEO & Director	1.13M	N/A	1970
Mr. Francis I. Perier Jr., M.B.A.	Chief Financial Officer	674.85k	N/A	1960
Dr. Badreddin Edris Ph.D.	Chief Operating Officer	844.74k	N/A	1987
Mr. Bhavesh Ashar	Chief Commercial Officer	821.61k	N/A	1966
Mr. Michael P. Nofi	Chief Accounting Officer	N/A	N/A	1971
Ms. Kim Diamond	VP of Communications & Investor Relations	N/A	N/A	N/A
Mr. Herschel S. Weinstein J.D.	Gen. Counsel & Sec.	N/A	N/A	1956
Mr. Daniel J. Pichl	Chief People Officer	N/A	N/A	1983
Dr. L. Mary Smith PH.D.	Chief Devel. Officer	N/A	N/A	1967
Dr. James Cassidy M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate governance

SpringWorks Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.